NCT03623321Phase 3Completed

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-05Actual
Enrollment · participants595Actual
Source updated2024-12-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview